Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.55 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.55 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 4/20 | 0.46 |
| ▸ | CTSL | P07711 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | PYGL | P06737 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 2/20 | 0.44 |
| ▸ | CCKBR | P32239 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24690962 | 1.00 | TAS1R3 (0.55) | TAS1R3TAS1R1CTSBCYP51A1CTSS | |
| SCHEMBL24690592 | 1.00 | TAS1R3 (0.55) | TAS1R3TAS1R1CTSBCYP51A1CTSS | |
| SCHEMBL24691288 | 0.91 | TAS1R3 (0.52) | TAS1R3TAS1R1CYP51A1CTSSCTSL | |
| SCHEMBL26233880 | 0.90 | TAS1R3 (0.56) | TAS1R3TAS1R1CTSBCYP51A1CTSS | |
| SCHEMBL24690752 | 0.89 | CTSB (0.54) | TAS1R3TAS1R1CTSBCTSSCTSL | |
| SCHEMBL24690777 | 0.88 | CTSB (0.50) | TAS1R3TAS1R1CTSBCYP51A1CTSS | |
| SCHEMBL26233853 | 0.88 | CTSB (0.50) | TAS1R3TAS1R1CTSBCYP51A1CTSS | |
| SCHEMBL24691105 | 0.88 | TAS1R3 (0.49) | TAS1R3TAS1R1CTSBCYP51A1CTSS | |
| SCHEMBL24691337 | 0.87 | TAS1R3 (0.49) | TAS1R3TAS1R1CTSBCYP51A1CTSS | |
| SCHEMBL24690790 | 0.87 | CTSB (0.49) | TAS1R3TAS1R1CTSBCYP51A1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322668-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACEA Therapeutics, Inc. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322668-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACEA Therapeutics, Inc. (US) | 2023-10-12 | — | — | US | disclosed |
| US-11753373-B2 | Protease inhibitors as antivirals | ACEA Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753373-B2 | Protease inhibitors as antivirals | ACEA Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230026438-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACEA Therapeutics, Inc. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026438-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACE, ACE2, TMPRSS15 | TAS1R3 1588/4885TAS1R1 1625/4885CTSB 44/4885 |
| US-11753373-B2 | Protease inhibitors as antivirals | ACE, ACE2, TMPRSS15 | TAS1R3 1588/4885TAS1R1 1625/4885CTSB 44/4885 |
| US-20230322668-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACE, ACE2, TMPRSS15 | TAS1R3 1588/4885TAS1R1 1625/4885CTSB 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.